MAPT and Alzheimer disease: Bi et al. (2020) suggested that dysfunction in the GABAergic system leads to neuronal excitatory/inhibitory imbalance, which in turn promotes the spread of Aβ and Tau pathology, exacerbating cognitive impairment in AD patients.